Search results for " Papillomavirus Infections"

showing 10 items of 12 documents

Efficacy and safety of human papillomavirus vaccination in HIV-infected patients: a systematic review and meta-analysis

2021

AbstractThe prophylactic vaccines available to protect against infections by HPV are well tolerated and highly immunogenic. People with HIV have a higher risk of developing HPV infection and HPV-associated cancers due to a lower immune response, and due to viral interactions. We performed a systematic review of RCTs to assess HPV vaccines efficacy and safety on HIV-infected people compared to placebo or no intervention in terms of seroconversion, infections, neoplasms, adverse events, CD4+ T-cell count and HIV viral load. The vaccine-group showed a seroconversion rate close to 100% for each vaccine and a significantly higher level of antibodies against HPV vaccine types, as compared to the …

0301 basic medicineCD4-Positive T-LymphocytesMaleDisease preventionHIV InfectionsAdolescent Adult Antibodies Viral CD4 Lymphocyte Count CD4-Positive T-Lymphocytes Female HIV Infections Humans Male Papillomavirus Infections Papillomavirus Vaccines Public Health Randomized Controlled Trials as Topic Risk Treatment Outcome Viral Load Virus Shedding Young Adult Patient SafetySettore MED/42 - Igiene Generale E ApplicataAntibodies Viral0302 clinical medicine030212 general & internal medicineViralRandomized Controlled Trials as TopicPublic healthMultidisciplinaryQHPV infectionRViral LoadAdolescent; Adult; Antibodies Viral; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Female; HIV Infections; Humans; Male; Papillomavirus Infections; Papillomavirus Vaccines; Public Health; Randomized Controlled Trials as Topic; Risk; Treatment Outcome; Viral Load; Virus Shedding; Young Adult; Patient SafetyVirus SheddingTreatment OutcomeMedicineFemalePublic HealthPatient SafetyViral loadAdultRiskmedicine.medical_specialtyAdolescentScienceHPV vaccinesPlaceboAntibodiesArticle03 medical and health sciencesPapillomavirus VaccinesYoung AdultInternal medicinemedicineHumansPapillomavirus VaccinesSeroconversionViral sheddingAdverse effectbusiness.industryPapillomavirus InfectionsHealth caremedicine.diseaseCD4 Lymphocyte Count030104 developmental biologybusinessScientific Reports
researchProduct

Italian Health Care Workers’ Knowledge, Attitudes, and Practices Regarding Human Papillomavirus Infection and Prevention

2020

Objective: To assess healthcare workers&rsquo

AdultMaleHealth Knowledge Attitudes Practicemedicine.medical_specialtyHPVknowledgegenetic structuresHealth PersonnelHealth Toxicology and MutagenesisUterine Cervical Neoplasmslcsh:MedicineScientific literatureimmunizationSettore MED/42 - Igiene Generale E ApplicataArticle03 medical and health sciences0302 clinical medicinepreventionAttitude Awareness Healthcare workers HPV Immunization Knowledge Practice Prevention Sexually transmitted infection Adult Cross-Sectional Studies Female Italy Middle Aged Papillomavirus Vaccines Papillomavirus Infections Uterine Cervical NeoplasmsSurveys and QuestionnairesvaccineIntervention (counseling)Health caremedicineHumansAttitude; Awareness; Healthcare workers; HPV; Immunization; Knowledge; Practice; Prevention; Sexually transmitted infection; VaccineawarenessPapillomavirus Vaccinessexually transmitted infection030212 general & internal medicineHuman papillomavirusbusiness.industryhealthcare workersPapillomavirus Infectionslcsh:RPublic Health Environmental and Occupational HealthMiddle AgedProduct characteristicspracticeCross-Sectional StudiesItaly030220 oncology & carcinogenesisFamily medicineattitudeMulticenter surveyPropensity score matchingFemalebusinessInternational Journal of Environmental Research and Public Health
researchProduct

Immunization Campaigns and Strategies against Human Papillomavirus in Italy: The Results of a Survey to Regional and Local Health Units Representativ…

2019

Objective. The study aimed to assess the impact of HPV immunization campaigns organizational aspects, the characteristics of immunization program (vaccination targets and type of offer), and communicative strategies adopted by four Italian administrative regions on vaccination coverage observed. Methods. From November 2017 to March 2018, regional and Local Health Units (LHUs) representatives were invited to complete an online survey including 54 questions evaluating vaccination invite systems, access systems to vaccination centres, reminder and recall systems, and adverse events surveillance. An overall descriptive analysis was conducted. Since observed vaccine coverage (VC) obtained in fem…

AdultMalemedicine.medical_specialtyArticle SubjectImmunization registryMEDLINElcsh:MedicineGeneral Biochemistry Genetics and Molecular Biology03 medical and health sciences0302 clinical medicine030225 pediatricsHealth careHumansMedicinePapillomavirus Vaccines030212 general & internal medicineHuman papillomavirusSurveyPapillomaviridaeCopaymentGeneral Immunology and MicrobiologyDescriptive statisticsImmunization Campaigns and StrategieImmunization Programsbusiness.industryPapillomavirus InfectionsVaccinationlcsh:RAdult; Female; Humans; Immunization Programs; Italy; Male; Papillomaviridae; Papillomavirus Infections; Papillomavirus Vaccines; VaccinationGeneral MedicineVaccinationHuman PapillomaviruItalyImmunizationFamily medicineFemalebusinessResearch ArticleBioMed Research International
researchProduct

Proliferative verrucous vs conventional leukoplakia: no significantly increased risk of HPV infection

2004

Proliferative verrucous leukoplakia (PVL) is a very aggressive form of oral leukoplakia (OL) with high morbidity and mortality rates, hypothesised to be linked to HPV infection. This study aimed to determine the presence of HPV DNA in PVL in comparison with OL, and in relation to social-demographical variables (age, gender, smoking and drinking habits) in an Italian multi-centric hospital-based study. The study group consisted of 58 cases of PVL and 90 cases of OL as controls (47 homogeneous (H) and 43 non-homogeneous (non-H) form), both recruited from four Italian cohorts. HPV DNA was identified in exfoliated mucosal cells by nested PCR (nPCR) with MY09/MY11 and GP5+/GP6+ primer pairs and …

AdultOralMaleCancer Researchmedicine.medical_specialtyGenotypeGastroenterologyVirusVerrucousRisk FactorsInternal medicineGenotypemedicineCarcinomaHumansCarcinoma VerrucousViralPapillomaviridaeRisk factorPapillomaviridaeLeukoplakiaAdult; Carcinoma; Verrucous; DNA; Viral; Female; Genotype; Humans; Leukoplakia; Oral; Male; Middle Aged; Papillomaviridae; Papillomavirus Infections; Risk Factors; SmokingbiologyCarcinomaPapillomavirus InfectionsSmokingHPV infectionvirus diseasesDNAMiddle Agedmedicine.diseasebiology.organism_classificationVirologyfemale genital diseases and pregnancy complicationsOncologyDNA ViralFemaleOral SurgeryLeukoplakia OralNested polymerase chain reactionLeukoplakia
researchProduct

TP53 codon 72 polymorphism and cervical cancer

2009

Background Cervical cancer is caused primarily by human papillomaviruses (HPV). The polymorphism rs1042522 at codon 72 of the TP53 tumour-suppressor gene has been investigated as a genetic cofactor. More than 80 studies were done between 1998 and 2006, after it was initially reported that women who are homozygous for the arginine allele had a risk for cervical cancer seven times higher than women who were heterozygous for the allele. However, results have been inconsistent. Here we analyse pooled data from 49 studies to determine whether there is an association between TP53 codon 72 polymorphism and cervical cancer.Methods Individual data on 7946 cases and 7888 controls from 49 different st…

ArginineMESH : Polymorphism GeneticMESH: Genes p53MESH : AgedPhysiologyUterine Cervical NeoplasmsMESH: Papillomavirus Infections[ SDV.CAN ] Life Sciences [q-bio]/Cancer0302 clinical medicineGenotypeMESH : FemaleCervical cancerGeneticsMESH: AgedMESH : Papillomavirus Infections0303 health sciencesMESH: Middle AgedHPV infectionMESH: Genetic Predisposition to DiseaseMiddle AgedMESH : AdultWILD-TYPE P53Hardy–Weinberg principle3. Good healthMESH: Uterine Cervical NeoplasmsOncologyMESH: Young Adult030220 oncology & carcinogenesisMeta-analysisFemaleAdultAdolescentMESH : Uterine Cervical NeoplasmsMESH : Young Adult[SDV.CAN]Life Sciences [q-bio]/CancerMESH : Genes p5303 medical and health sciencesYoung AdultSQUAMOUS INTRAEPITHELIAL LESIONSMESH : AdolescentINDIAN WOMENMESH: Polymorphism GeneticmedicineHumansGenetic Predisposition to DiseaseMESH : Middle AgedAllele030304 developmental biologyAgedMESH: AdolescentMESH: HumansPolymorphism GeneticHUMAN-PAPILLOMAVIRUS TYPE-16business.industryP53 ARG72PRO POLYMORPHISMHEALTHY WOMENPapillomavirus InfectionsMESH : HumansMESH: AdultOdds ratiomedicine.diseaseGenes p53GENOTYPESHARDY-WEINBERG EQUILIBRIUMRISK-FACTORSMESH : Genetic Predisposition to DiseasebusinessMESH: FemaleHPV INFECTIONLancet Oncology
researchProduct

Sodium butyrate with UCN-01 has marked antitumour activity against cervical cancer cells.

2010

The effect of combining sodium butyrate (NaB), a histone deacetylase inhibitor, and 7-hydroxy-staurosporine (UCN-01) on cytotoxicity in human cervical carcinoma cells was evaluated.HeLa and CaSki cells were treated using NaB alone or in combination with staurosporine (STS) or its analog UCN-01. Cytotoxicity was determined by flow cytometry and morphological assays. Apoptotic pathways were characterized by Western blotting and immunostaining. CaSki cells were also xenografted into nude mice to assess the in vivo effects of NaB/UCN-01 combination.Treatment with NaB and STS or UCN-01 resulted in enhanced apoptosis of cancer cells. Apoptosis involved mitochondrial pathways and overexpression of…

MESH : StaurosporineMESH : Hela CellsMESH : Antineoplastic Combined Chemotherapy Protocolshealth care facilities manpower and servicesUterine Cervical NeoplasmsMESH: ButyratesMESH: Cell CycleApoptosisMESH: Papillomavirus Infections[ SDV.CAN ] Life Sciences [q-bio]/CancerMiceAntineoplastic Combined Chemotherapy ProtocolsMESH: AnimalsMESH: Human papillomavirus 18MESH : Human papillomavirus 18MESH : Femalehealth care economics and organizationsMESH: Human papillomavirus 16MESH : Papillomavirus InfectionsHuman papillomavirus 16Human papillomavirus 18Cell CycleMESH : Mice NudeMESH: Uterine Cervical NeoplasmsMESH: Antineoplastic Combined Chemotherapy ProtocolsButyratesMESH: Cell Growth ProcessesFemaleMESH: Xenograft Model Antitumor Assaysendocrine systemMESH: Cell Line TumoreducationMESH : Uterine Cervical NeoplasmsMice Nude[SDV.CAN]Life Sciences [q-bio]/CancerCell Growth ProcessesMESH : Xenograft Model Antitumor Assays[SDV.CAN] Life Sciences [q-bio]/CancerCell Line TumorMESH : ButyratesMESH : MiceMESH : Cell CycleMESH: Mice Nudeotorhinolaryngologic diseasesAnimalsHumansMESH: MiceMESH: HumansMESH : Cell Line TumorMESH: ApoptosisPapillomavirus InfectionsMESH : HumansMESH : Human papillomavirus 16StaurosporineXenograft Model Antitumor AssaysMESH: Hela CellsMESH : Cell Growth ProcessesMESH: StaurosporineMESH : AnimalsMESH: FemaleMESH : ApoptosisHeLa Cells
researchProduct

[Vaccination against papillomavirus : arguments and evidence of effectiveness].

2020

Vaccination against papillomavirus: arguments and evidence of effectiveness. Vaccination against human papillomavirus is a major advance in the prevention of cervical cancer. Evidence of its effectiveness has accumulated over the past thirty years since basic research has demonstrated the ability of viral pseudoparticles to induce immune responses in animals. Large human clinical trials followed to demonstrate the safety and efficacy of vaccination against targeted HPV infections and their associated lesions. After its approval and marketing the vaccine efficacy was measured at the level of entire populations, confirming its effectiveness and medical interest. Today, models predict a possib…

MESH: HumansPapillomavirus InfectionsVaccinationUterine Cervical Neoplasms[SDV.CAN]Life Sciences [q-bio]/CancerMESH: Papillomavirus VaccinesMESH: VaccinationMESH: Papillomavirus InfectionsMESH: Uterine Cervical Neoplasms[SDV.CAN] Life Sciences [q-bio]/CancerHumansFemalePapillomavirus VaccinesDisease EradicationMESH: FemaleLa Revue du praticien
researchProduct

Overview of the benefitsand potential issues of the nonavalent HPV vaccine

2017

HPV-related diseases affect anogenital and oropharyngeal regions, heavily affecting the psychosexual dimension of both male and female individuals. HPV vaccination programs based on a bivalent or quadrivalent vaccine have opened broad perspectives for primary prevention. A nonavalent HPV vaccine (9vHPV), covering nine genotypes (HPV6, HPV11, HPV16, HPV18, HPV31, HPV33, HPV45, HPV52, and HPV58), might provide further improvement in terms of direct protection. In the present report, efficacy and safety data from 9vHPV vaccine development programs are examined. Efficacy data come from a pivotal trial, which was conducted among women aged 16–26 years randomly assigned to receive either the 9vHP…

MaleHPVmedicine.medical_specialtyUterine Cervical NeoplasmsDiseaseAnatomic region03 medical and health sciences0302 clinical medicineHPV nonavalent vaccinePrimary preventionEnvironmental healthmedicineHumansPapillomavirus Vaccines030212 general & internal medicineCervical cancer; HPV; HPV nonavalent vaccine; Prevention; Female; Humans; Male; Papillomaviridae; Papillomavirus Infections; Papillomavirus Vaccines; Randomized Controlled Trials as Topic; Uterine Cervical NeoplasmsPapillomaviridaeRandomized Controlled Trials as TopicGynecologyCervical cancerbusiness.industryPreventionPapillomavirus InfectionsObstetrics and GynecologyHpv vaccinationGeneral Medicinemedicine.disease030220 oncology & carcinogenesisCervical cancer; HPV; HPV nonavalent vaccine; PreventionCervical cancerFemalebusiness
researchProduct

Human papilloma virus infection and vaccination: Pre-post intervention analysis on knowledge, attitudes and willingness to vaccinate among preadolesc…

2020

In recent years, vaccination coverage rates against Human Papilloma Virus (HPV) in Europe have shown a decreasing trend and remain below the required standard. The present study aims to assess knowledge and attitudes regarding HPV infection and vaccination among a representative sample of preadolescents of Palermo, Italy. A survey was carried out throughout two questionnaires, before and after carrying out an educational intervention scheduled during school hours. A total of 1702 students attending first-grade secondary schools of the province of Palermo were enrolled (response rate 68.9%). Students attending third classes (adj OR = 1.18

MaleHealth Knowledge Attitudes PracticeHealth Toxicology and Mutagenesislcsh:MedicineUterine Cervical NeoplasmsAdult women0302 clinical medicineSurveys and Questionnaires030212 general & internal medicineChildPapillomaviridaeSicilyPapillomavirus VaccineResponse rate (survey)PracticeSchoolsSchool-based interventionHealth KnowledgeVaccinationPreadolescent studentHPV infectionSexually transmitted diseaseVaccinationEuropeKnowledgeHPV infection; HPV vaccine; attitude; knowledge; preadolescent students; school-based intervention; sexually transmitted diseases; vaccination; willingness; Child; Europe; Female; Humans; Male; Papillomavirus Infections; Papillomavirus Vaccines; Patient Acceptance of Health Care; Schools; Sicily; Surveys and Questionnaires; Uterine Cervical Neoplasms; Vaccination; Health Knowledge Attitudes Practice; PapillomaviridaeFemalewillingnesspreadolescent studentssexually transmitted diseaseseducationWillingneArticlePost-interventionLikert scale03 medical and health sciences030225 pediatricsmedicineHumansHuman papilloma virus infectionPapillomavirus VaccinesSocioeconomic statusPapillomavirus InfectionHPV vaccinebusiness.industrylcsh:RPapillomavirus InfectionsPublic Health Environmental and Occupational HealthPatient Acceptance of Health Caremedicine.diseaseAttitudeAttitudesHPV infectionbusinessDemography
researchProduct

Human papillomavirus infections and upper aero-digestive tract cancers: the ARCAGE study.

2013

Human papillomavirus (HPV) is causally implicated in a subset of cancers of the upper aero-digestive tract (UADT). Methods Associations between type-specific HPV antibodies were examined among 1496 UADT cancer case subjects and 1425 control subjects by estimating odds ratios (ORs) in logistic regression analyses adjusted for potential confounders. The agreement between serology and tumor markers of HPV infection, including presence of HPV DNA and p16 expression, were examined in a subset of tumors. Results HPV16 L1 seropositivity was associated with increased risk of oral cavity and oropharyngeal cancer (OR = 1.94, 95% confidence interval [CI] = 1.03 to 3.65; OR = 8.60, 95% CI = 5.21 to 14.…

OncologyMaleCancer Researchmedicine.medical_specialtyvirusesPapillomavirus E7 ProteinsFluorescent Antibody TechniqueBiologyAntibodies ViralPolymerase Chain ReactionSerologyInternal medicinemedicineBiomarkers TumorOdds RatioHumansLaryngeal NeoplasmsAgedNeoplasm StagingHuman papillomavirus 16ConfoundingPapillomavirus InfectionsCase-control studyHPV infectionCancervirus diseasesOdds ratioOncogene Proteins ViralMiddle Agedmedicine.diseasefemale genital diseases and pregnancy complicationsUp-RegulationRepressor ProteinsOropharyngeal NeoplasmsOropharyngeal NeoplasmLogistic ModelsOncologyCase-Control StudiesImmunologyHuman papillomavirus 16; Oropharyngeal Neoplasms; Papillomavirus InfectionsDNA ViralEtiologyFemaleJournal of the National Cancer Institute
researchProduct